AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04402944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 2.5 mL BID
Study NCT02237885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSky MindWave Mobile
Study NCT02916056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 5mg
Study NCT03978806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: peer navigator
Description: The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
Study NCT03643822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
Study NCT03978806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control Arm (standard of care)
Description: Control patients will have met the same inclusion and exclusion criteria as intervention patients.
Study NCT04035993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving with a driving simulator
Description: Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes.
Study NCT04027907 — intervention group
Intervention type: OTHER
Intervention: Flowcytometry
Description: detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
Study NCT03643822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
Study NCT03643822 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Control/Placebo intervention
Study NCT03643822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Control/Placebo intervention
Study NCT02260570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: COMT Inhibitor
Study NCT02260570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A pill that contains no active ingredient
Study NCT04273763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablets
Description: Bromhexine Hydrochloride Tablets
Study NCT04273763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol Hydrochloride Granules
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
Study NCT04273763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbidol Hydrochloride Granules
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
Study NCT04273763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon α2b Spray
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
Study NCT04273763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Interferon α2b Spray
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
Study NCT02684370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study NCT02684370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by subcutaneous (SC) injection
Study NCT02684370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by subcutaneous (SC) injection
Study NCT02684370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: Ustekinumab administered by subcutaneous (SC) injection
Study NCT02684370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab administered by subcutaneous (SC) injection
Study NCT01112384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: Given orally 3 times per week
Study NCT01787084 — intervention group
Intervention type: DEVICE
Intervention: Edwards SAPIEN Transcatheter Heart Valve
Description: Non-femoral transcatheter delivery of heart valve
Study NCT02399085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: 12 mg/kg
Study NCT02399085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg
Study NCT04146480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F18-NaF PET/CT
Description: The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions.
Study NCT01859715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
Study NCT01859715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
Study NCT01859715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
Study NCT04242056 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PM-PBB3
Description: 18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets.
Study NCT04487327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.
Study NCT04487327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.
Study NCT01825369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV L-carnitine
Description: See arm description
Study NCT00714246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Study NCT00714246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Study NCT02684370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab administered by subcutaneous (SC) injection
Study NCT00627094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biatain
Description: A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
Study NCT00627094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ibu
Description: Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
Study NCT01650142 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01861431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Sexual Risk reduction
Description: 4 sessions of HIV sexual risk reduction
Study NCT01861431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Sexual Risk reduction plus Microfinance
Description: 4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
Study NCT04238494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR)
Description: Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
Study NCT04238494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nuclear magnetic resonance (NMR)
Description: Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
Study NCT01232075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended letrozole regimen
Description: Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .
Study NCT01232075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate regimen
Description: Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .
Study NCT00399204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone vs Metformin
Study NCT00399204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone vs Metformin
Study NCT00308555 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Study NCT00380861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement using the PFC Sigma RPF knee implant.
Description: Total knee replacement
Study NCT00380861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement using the PFC Sigma RP knee implant
Description: Total knee replacement
Study NCT00641810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine reduction
Description: Reduction in daily caffeine consumption from usual amounts to none.
Study NCT01269671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin, Peppermint Oil (mentharil), and Simethicone
Description: Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
Study NCT01269671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
Study NCT00968539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections
Study NCT00968539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340269A
Description: Two intramuscular injections
Study NCT01469845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Description: 4 ml dose to be administered every 6 hours
Study NCT03464110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: . The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
Study NCT00714246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Study NCT03192917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shock wave treatment (LI-ESWT)
Description: Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
Study NCT00833924 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zenith(R) Low Profile AAA Endovascular Graft
Description: The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
Study NCT01495481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 2 mcg/kg, Intravenous push
Study NCT01495481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
Study NCT02126969 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose fractionated radiation - 80cGy with chemotherapy
Description: Chemotherapy + 80 cGy of RT
Study NCT02126969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Carboplatin AUC 6
Description: Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
Study NCT03192917 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity extracorporeal shock wave treatment (LI-ESWT) sham
Description: A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
Study NCT02181673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
Study NCT02181673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
Study NCT02181673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally once daily
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone
Description: Orally once daily
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitolisib
Description: Orally once daily
Study NCT02181673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
Study NCT03176953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: active medication
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Orally once daily
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once daily
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally bid
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Orally bid
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Orally bid
Study NCT01485861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Orally bid
Study NCT02468466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level suicide prevention programs
Description: The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.